Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Daiichi Sankyo Ltd ADR (OP: DSNKY ) 36.29 +0.07 (+0.20%) Streaming Delayed Price Updated: 11:26 AM EDT, Jul 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 11,518 Open 36.07 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 36.22 Today's Range 36.07 - 36.41 52wk Range 23.72 - 37.72 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug June 27, 2024 The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The... Via Benzinga Exposures Product Safety Why Is AstraZeneca Stock Trading Lower On Tuesday? May 28, 2024 AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance. Via Benzinga Performance YTD +33.97% +33.97% 1 Month -1.54% -1.54% 3 Month +17.45% +17.45% 6 Month +28.65% +28.65% 1 Year +27.34% +27.34% More News Read More DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023 April 30, 2024 Via InvestorPlace Double Good News For AstraZeneca's Breast Cancer Drugs April 29, 2024 Via Benzinga AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor April 08, 2024 Via Benzinga Exposures Product Safety Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact March 20, 2023 Via Benzinga Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine January 13, 2023 Via Benzinga This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says September 12, 2022 Via Benzinga What's Going On With Pfizer Stock Today? January 25, 2024 Via Benzinga Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today January 03, 2024 Via Benzinga Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider December 20, 2023 Via Benzinga Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now? October 31, 2023 Via The Motley Fool Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting September 22, 2023 Via Benzinga AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials September 11, 2023 Via Benzinga FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt July 21, 2023 Via Benzinga Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More July 04, 2023 Via Benzinga AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial July 03, 2023 Via Benzinga Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines June 27, 2023 Via Benzinga AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting March 06, 2023 Via Benzinga Is Gilead Sciences a Good Stock to Buy Now? February 06, 2023 Via The Motley Fool AstraZeneca’s Next “Wonder Drug” January 19, 2023 Via Talk Markets AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs December 19, 2022 Via Benzinga AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients December 09, 2022 Via Benzinga European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs November 14, 2022 Via Benzinga With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma September 21, 2022 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
